Advertisement
Advertisement
NRSN
NeuroSense Therapeutics Ltd. Ordinary Shares
0.88
USDSponsored
0.00
+0.34%
May 08, 15:59 UTC -4
Closed
After-Market
0.88
0.00
+0.23%
NRSN Earnings Reports
Positive Surprise Ratio
NRSN beat 6 of 9 last estimates.
67%
Next Report
Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$273.36K
/-$0.12
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-36.84%
NeuroSense Therapeutics Ltd. Ordinary Shares earnings per share and revenue
On Mar 31, 2026, NRSN reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.10 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.48% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.12 USD, with revenue projected to reach 273.36 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were NeuroSense Therapeutics Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, NeuroSense Therapeutics Ltd. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to NeuroSense Therapeutics Ltd. Ordinary Shares's Q4 2025 earnings?
The stock price moved up 5.48%, changed from $0.73 before the earnings release to $0.77 the day after.
When is NeuroSense Therapeutics Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Jul 30, 2026.
What are the forecasts for NeuroSense Therapeutics Ltd. Ordinary Shares's next earnings report?
Based on --
analysts, NeuroSense Therapeutics Ltd. Ordinary Shares is expected to report EPS of -$0.12 and revenue of $273.36K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement